Financial Performance - The company's revenue for Q1 2024 was ¥91,814,686.88, representing a 9.27% increase compared to ¥84,021,879.90 in the same period last year[5] - Net profit attributable to shareholders for Q1 2024 was ¥19,890,650.72, up 10.56% from ¥17,991,124.69 in the previous year[5] - The total operating revenue for Q1 2024 was CNY 91,814,686.88, an increase of 9.6% compared to CNY 84,021,879.90 in the same period last year[20] - The net profit for Q1 2024 was CNY 19,593,040.69, an increase of 5.54% compared to CNY 18,564,740.94 in Q1 2023[22] - The operating profit for Q1 2024 was CNY 23,846,785.88, up from CNY 21,863,324.32 in the same period last year, reflecting a growth of 9.05%[22] Cash Flow and Assets - The net cash flow from operating activities increased by 86.66% to ¥23,671,274.75, compared to ¥12,681,513.81 in the same period last year[5] - Cash received from tax refunds decreased by 78.00%, totaling 1,023,901.53 compared to 4,653,971.94 in the prior period[9] - Cash payments for various taxes decreased by 48.97%, amounting to 12,733,922.03 compared to 24,953,627.21 previously[9] - The cash and cash equivalents at the end of Q1 2024 were CNY 237,281,126.32, down from CNY 698,422,931.47 at the end of Q1 2023[24] - The company's cash and cash equivalents decreased by 57.87% to ¥239,682,701.32 from ¥568,855,578.18 at the beginning of the year[8] Investment and Expenses - The company reported a significant increase in investment income, rising 6748.64% to ¥12,082,100.02 from ¥176,416.07 in the previous year[8] - The company experienced a 34285.78% increase in non-operating expenses, reaching 104,464.00 due to charitable donations[9] - Research and development expenses decreased to CNY 4,804,803.02 from CNY 6,275,458.33, a reduction of 23.49%[22] - Investment activities resulted in a net cash outflow of CNY 326,688,357.82, an improvement from a net outflow of CNY 405,993,575.12 in Q1 2023[24] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 12,336[11] - The company repurchased a total of 1,235,051 shares, representing 1.23% of the total share capital, with a total transaction amount of CNY 24,983,242.50[15] Asset Management - The total assets at the end of Q1 2024 were ¥2,358,116,976.03, a decrease of 1.48% from ¥2,393,581,909.51 at the end of the previous year[5] - The total liabilities decreased to CNY 117,304,628.05 from CNY 147,371,481.33, a reduction of 20.4%[19] - The company’s equity attributable to shareholders was CNY 2,233,616,215.44, slightly down from CNY 2,238,716,685.61[19] Future Outlook - The company has ongoing investments in new technologies and products, although specific details were not provided in the report[18] - The company plans to continue its market expansion and may consider further acquisitions in the future[18]
东星医疗(301290) - 2024 Q1 - 季度财报